Diabetes Drugs May Ease Hidradenitis Suppurativa and Heart Risk, Study Suggests

A new retrospective analysis from researchers at the Icahn School of Medicine at Mount Sinai, published in the Archives of Dermatological Research, examines whether glucagon-like peptide-1 receptor agonists, the class of metabolic drugs that includes semaglutide, could do more than lower blood sugar and body weight in patients with hidradenitis suppurativa. The study, led by Megan Lau, Dev Patel, and Kristina Navrazhina, with senior author Emma Guttman-Yassky, set out to assess the role of these agents in reducing cardiovascular risk, systemic inflammation, and disease severity in a patient population that carries a heavy burden of metabolic and cardiovascular disease. Although the work is presented as a research letter and is cross-sectional and retrospective in design, it lands at the intersection of two of the most active conversations in modern medicine: the exploding off-label interest in GLP-1 drugs and the long-neglected systemic health consequences of a chronic, stigmatizing skin disease.

Hidradenitis suppurativa, often abbreviated HS, is a chronic inflammatory skin condition that affects intertriginous areas of the body, most commonly the armpits, groin, and under the breasts. It is driven by follicular occlusion and an aberrant immune response, producing painful nodules, abscesses, draining tunnels known as fistulas, and ultimately scarring. The disease typically begins after puberty, follows a relapsing course, and is associated with profound quality-of-life impairment. Prevalence estimates vary, but HS is recognized as substantially underdiagnosed, with many patients waiting years for a correct diagnosis. Current treatment spans topical and systemic antibiotics, hormonal therapies, immunosuppressants, and biologic agents targeting tumor necrosis factor, yet many patients fail to achieve durable disease control with existing options.

What makes HS particularly compelling as a target for metabolic intervention is its tight epidemiological association with the metabolic syndrome. Patients with HS are disproportionately affected by obesity, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease, and the severity of skin disease tends to track with metabolic comorbidity. Previous literature, including work cited by the Mount Sinai team, has framed HS as a disease in which systemic inflammation and metabolic dysfunction reinforce one another. This bidirectional relationship raises an obvious therapeutic question: if weight loss and improved metabolic health dampen the inflammatory drive behind HS, could drugs engineered for diabetes and obesity also improve the skin disease itself, while simultaneously attacking the cardiovascular risk that shortens patients’ lives?

GLP-1 receptor agonists are a mechanistically plausible answer. Glucagon-like peptide-1 is an incretin hormone released by intestinal cells after eating; it potentiates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and acts on hypothalamic pathways that reduce appetite. Receptor agonists such as semaglutide and related molecules mimic these effects, producing substantial weight loss and glycemic control. Beyond metabolism, the class has documented anti-inflammatory properties, and large cardiovascular outcome trials in patients with type 2 diabetes demonstrated reductions in major adverse cardiovascular events, effects that appear to extend beyond what weight loss alone would explain. The receptor is expressed on immune cells, and GLP-1 signaling has been linked to modulation of inflammatory cytokine production, which is precisely the kind of biology that could matter in a TNF- and interleukin-driven skin disease like HS.

The Mount Sinai group approached the question with a cross-sectional retrospective analysis, a design that mines existing clinical data to compare outcomes between patients exposed to a drug and those who were not. The authors explicitly framed their aims around three endpoints: cardiovascular risk, inflammation, and HS disease severity. The research letter format means the study is concise and hypothesis-generating rather than definitive, and the authors themselves note that no datasets were generated or analyzed beyond the retrospective clinical review. Retrospective designs of this kind are vulnerable to confounding by indication, since patients prescribed GLP-1 agonists typically differ from those who are not in weight, diabetes status, and access to care, and the authors’ choice of a research letter signals an appropriately cautious interpretation of their findings.

The study does not stand in isolation. It builds on a small but growing clinical literature exploring GLP-1 drugs in HS. A 2024 study published in the British Journal of Dermatology reported on semaglutide used for weight loss as an adjunctive treatment in patients with HS and obesity, describing its impact on disease control and quality of life. In the same year, a retrospective cohort study using the TriNetX database, published in the Journal of the American Academy of Dermatology, examined whether semaglutide use was associated with decreased HS-related resource utilization, including emergency department visits. The Mount Sinai team also cites real-world data on biologic therapy in HS that included lipid profile evaluation, underscoring how dermatologists are increasingly attentive to the cardiovascular dimension of the disease. Together, these threads suggest a field in transition, where HS is being reconceived not merely as a skin disorder but as a systemic inflammatory condition with metabolic consequences.

The conceptual appeal of the GLP-1 hypothesis lies in its dual action. Conventional HS biologics suppress specific immune pathways but do nothing for the metabolic comorbidities that fuel inflammation and cardiovascular risk. A drug that simultaneously reduces body weight, improves insulin sensitivity, lowers systemic inflammatory tone, and has proven cardiovascular benefit would address several facets of the disease at once. For patients, the practical implications could be significant: fewer painful flares, better response to existing therapies, and reduced long-term risk of heart attack and stroke, which epidemiological studies consistently show to be elevated in HS populations. The possibility that a single prescription could improve skin, metabolism, and cardiovascular outlook explains why the topic has generated such intense interest among both dermatologists and the public.

At the same time, the evidence base remains early. Cross-sectional retrospective analyses can identify associations and generate hypotheses, but they cannot establish causation, and unmeasured confounders are a persistent threat. Randomized, prospective trials will be needed to determine whether GLP-1 receptor agonists genuinely reduce HS severity independent of weight loss, whether the anti-inflammatory effects observed systemically translate to the skin, and what the optimal patient population, dosing, and combination strategies would be. Questions also remain about durability, cost, and tolerability, since gastrointestinal side effects are common and long-term therapy is typically required to maintain benefit. The authors’ disclosures, which include extensive consulting relationships across the dermatology and immunology industry, reflect how commercially active this therapeutic space has become.

Nevertheless, the study adds a meaningful data point to a rapidly evolving conversation. It comes from one of the world’s leading inflammatory skin disease centers, at a moment when GLP-1 receptor agonists are being tested or considered across an astonishing range of conditions, from kidney disease and sleep apnea to addiction and neurodegeneration. For the HS community, which has historically received less research attention and fewer approved therapies than other immune-mediated diseases, the prospect of repurposing a well-characterized drug class with established cardiovascular safety data is genuinely exciting. If future trials confirm what this retrospective analysis and its predecessors hint at, GLP-1 receptor agonists could reshape HS management by treating the skin disease and its most dangerous comorbidities in parallel, turning a metabolic drug into an unexpected ally for patients whose burden extends far beneath the skin.

Subject of Research: The role of GLP-1 receptor agonists in reducing cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa

Article Title: Cross-sectional retrospective analysis assessing the role of GLP-1 receptor agonists in reducing cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa

Article References: Lau, M., Patel, D., Navrazhina, K., Largen, J., Liu, D., Wang, D., Ayub, M., Ungar, B., & Guttman-Yassky, E. (2026). Cross-sectional retrospective analysis assessing the role of GLP-1 receptor agonists in reducing cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa. Archives of Dermatological Research, 318(1), Article 481. https://doi.org/10.1007/s00403-026-04968-y

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04968-y

Keywords: hidradenitis suppurativa, GLP-1 receptor agonists, semaglutide, cardiovascular risk, inflammation, metabolic syndrome, obesity, type 2 diabetes, dermatology, retrospective study, biologic therapy, Mount Sinai